CRIS Current Research Information System

CATANI, LUCIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.188
EU - Europa 2.793
AS - Asia 1.326
AF - Africa 194
SA - Sud America 13
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 1
Totale 8.521
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.170
GB - Regno Unito 742
SE - Svezia 546
IT - Italia 477
VN - Vietnam 412
DE - Germania 359
CN - Cina 331
SG - Singapore 261
IN - India 199
IE - Irlanda 162
FR - Francia 111
RU - Federazione Russa 86
TG - Togo 74
UA - Ucraina 68
EE - Estonia 59
ZA - Sudafrica 52
BG - Bulgaria 49
JO - Giordania 46
CH - Svizzera 40
CI - Costa d'Avorio 36
BE - Belgio 34
FI - Finlandia 27
NG - Nigeria 24
TR - Turchia 24
IR - Iran 19
CA - Canada 18
BR - Brasile 8
JP - Giappone 8
MY - Malesia 8
ES - Italia 5
HK - Hong Kong 5
SC - Seychelles 5
AT - Austria 4
AU - Australia 4
PL - Polonia 4
CL - Cile 3
CZ - Repubblica Ceca 3
GR - Grecia 3
LB - Libano 3
RO - Romania 3
BD - Bangladesh 2
GH - Ghana 2
HR - Croazia 2
HU - Ungheria 2
IL - Israele 2
NL - Olanda 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CO - Colombia 1
GE - Georgia 1
ID - Indonesia 1
LT - Lituania 1
MA - Marocco 1
PK - Pakistan 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
TH - Thailandia 1
VE - Venezuela 1
Totale 8.521
Salva come PNG Salva come JPEG
Città #
Southend 663
Fairfield 535
Chandler 524
Ashburn 366
Dong Ket 263
Woodbridge 237
Houston 226
Seattle 223
Wilmington 219
Cambridge 216
Singapore 210
Ann Arbor 195
Princeton 171
Dublin 162
Bologna 102
Lomé 74
Westminster 66
Nanjing 64
Bremen 54
Padova 52
Redmond 50
Sofia 49
Amman 46
Beijing 45
Turin 42
Jinan 41
Milan 41
New York 41
Berlin 40
Santa Clara 40
Shenyang 40
Abidjan 36
Brussels 34
Bern 33
Hyderabad 32
San Diego 31
Saint Petersburg 30
Helsinki 27
Florence 26
Jacksonville 24
Abeokuta 21
Los Angeles 21
Medford 20
Nanchang 18
Burdur 17
Redwood City 17
Falls Church 16
Hebei 16
Changsha 15
Boardman 14
Norwalk 14
Fremont 12
Zhengzhou 12
Dearborn 11
Des Moines 11
Tianjin 11
Boydton 9
Bühl 9
Hangzhou 9
Monheim 9
Perugia 9
Taiyuan 9
Hefei 8
Leawood 8
Rome 8
Toronto 8
Jiaxing 7
Kuala Lumpur 7
Limidi 7
Mountain View 7
Paris 7
Tokyo 7
Zanjan 7
Andover 6
Ningbo 6
Olalla 6
Pune 6
San Francisco 6
Casalecchio di Reno 5
Guangzhou 5
Henderson 5
Kuban 5
London 5
Mahé 5
Winnipeg 5
Boston 4
Canzo 4
Cernusco sul Naviglio 4
Chicago 4
Frankfurt am Main 4
Haikou 4
Madrid 4
Migliarino 4
Modena 4
Mülheim 4
Parma 4
Plauen 4
São Paulo 4
Caprino Veronese 3
Ferrara 3
Totale 5.874
Salva come PNG Salva come JPEG
Nome #
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 190
A novel model of CCl4-induced cirrosi with ascites in the mouse. 180
Bleeding in essential thrombocythaemia: a retrospective analysis on 565 patients 168
Comparison of JAK2V617F-positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology 159
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 156
Absence of bi-directional cross-resistance of thrombopoietin receptor agonists in chronic refractory immune thrombocytopenia: possible role ofMPLpolymorphisms 153
Gene expression profiling of normal and malignant CD34-derived megakaryocytic cells. 149
Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. 148
Association of essential thrombocythemia and non-Hodgkin lymphoma: a single-centre experience 145
Human cord blood-derived platelet lysate enhances the therapeutic activity of adipose-derived mesenchymal stromal cells isolated from Crohn's disease patients in a mouse model of colitis 141
CIRCULATING PLATELET AND MEGAKARYOCYTE-DERIVED MICROPARTICLES OF JAK2V617F MUTATED PATIENTS WITH MYELOFIBROSIS ARE DISREGULATED: A NOVEL LIQUID BIOPSY TOOL OF RESPONSE TO RUXOLITINIB? 140
Circulating CD4+CD25-Foxp3+ cells are increased in patients with immune thrombocytopenia 138
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 138
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 138
CIRCULATING CD34+ STEM/PROGENITOR CELLS FROM TRIPLE NEGATIVE PATIENTS WITH MYELOFIBROSIS SHOW DIFFERENT NUMBER, GENE EXPRESSION PROFILE AND IN VITRO RESPONSE TO INFLAMMATORY STIMULI AS COMPARED WITH THE JAK2(V617F) MUTATED COUNTERPARTS 138
Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury. 135
Decreased expression of indoleamine 2,3-dioxygenase 1 in dendritic cells contributes to impaired regulatory T cell development in immune thrombocytopenia 134
Mobilized Peripheral Blood versus Cord Blood: Insight into the distinct role of proinflammatory cytokines on survival, clonogenic ability, and migration of CD34+ cells 132
Disease-specific derangement of circulating endocannabinoids and n-acylethanolamines in myeloproliferative neoplasms 131
Circulating Platelet Vs Megakaryocyte-Derived Microparticles Identify Myelofibrosis Patients with JAK2V617F Mutation, High Disease Burden and Ruxolitinib Response 129
Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis 128
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 124
Crucial Factors of the Inflammatory Microenvironment (IL-1 beta/TNF-alpha/TIMP-1) Promote Maintenance of the Malignant Hemopoietic Clone of Myelofibrosis By Stimulating the in Vitro Survival/Proliferation/Migration of Circulating CD34+ stem/Progenitor Cells 122
Very elderly patients with essential thrombocythaemia: are they a separate category? A monocentric study on 118 patients older than 75 years 121
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 118
The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric study 117
The tissue inhibitor of metalloproteinases-1 (TIMP-1) promotes survival and migration of acute myeloid leukemia cells through CD63/PI3K/Akt/p21 signaling 116
Reinfusion of highly purified CD133+ bone marrow-derived stem/progenitor cells in patients with end-stage liver disease: a phase I clinical trial 109
The tissue inhibitor of metalloproteinases 1 increases the clonogenic efficiency of human hematopoietic progenitor cells through CD63/PI3K/Akt signaling 109
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 108
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 108
null 107
Distinct profile of CD34+ cells and plasma-derived extracellular vesicles from triple-negative patients with Myelofibrosis reveals potential markers of aggressive disease 107
Regulatory T cells from patients with end-stage organ disease can be isolated, expanded and cryopreserved according good manufacturing practice improving their function 106
A specific host/microbial signature of plasma-derived extracellular vesicles is associated to thrombosis and marrow fibrosis in polycythemia vera 106
Molecular and functional characterization of CD133+stem/progenitor cells infused in patients with end-stage liver disease reveals their interplay with stromal liver cells 106
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy 105
Increased transcription of mitochondrial genes for Complex I in human platelets during ageing 104
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. 103
SuperB: A High-Luminosity Asymmetric e+ e- Super Flavor Factory. Conceptual Design Report 102
An Abnormal Host/Microbiomes Signature of Plasma-Derived Extracellular Vesicles Is Associated to Polycythemia Vera 102
Stem cell mobilization and collection in patients with liver cirrhosis. 101
JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients 101
The choice of second-line therapy in steroid-resistant immune thrombocytopenia: Role of platelet kinetics in a single-centre long-term study 101
Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia. 101
Mobilization of bone marrow-derived hematopoietic and endothelial stem cells after orthotopic liver transplantation and liver resection. 100
GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF) ADMINISTRATION IN CIRRHOTIC PATIENTS: A PHASE II STUDY EVALUATING TOLERABILITY PROFILE AND MOBILIZATION OF HAEMATOPOIETIC STEM CELLS (HSCS). 100
Romiplostim as early treatment of immune thrombocytopenia with severe immunodeficiency 99
null 98
MYH9-related thrombocytopenia and intracranial bleedings: a complex clinical/surgical management and review of the literature 96
null 96
The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engrftment. 96
Partial splenic embolization preceding splenectomy, in a case of refractory immune thrombocytopenic purpura. 91
Understanding how older age drives decision-making and outcome in Immune Thrombocytopenia. A single centre study on 465 adult patients 91
Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms 89
The Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) Regulates the Function and Migration of Leukemic Blasts through CD63/PI3K/AKT/P21 Axis 89
Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study 88
null 86
TOWARD THE IDENTIFICATION OF A MICRORNA-BASED SIGNATURE OF CIRCULATING MICROPARTICLES FROM TRIPLE NEGATIVE AND JAK2(V617F) MUTATED PATIENTS WITH MYELOFIBROSIS 86
STUDIO DELLA FUNZIONE E DEL PROFILO DEI MICRORNA IN MICROPARTICELLE CIRCOLANTI ISOLATE DA PAZIENTI ‘TRIPLI NEGATIVI’ E JAK2V617F MUTATI CON MIELOFIBROSI 85
The CD47 pathway is deregulated in human immune thrombocytopenia 82
Platelet fluctuations during thrombopoietin-receptor agonist treatment: correlation with platelet apoptosis 82
Platelet lysate enhances the therapeutic activity of Adipose Derived Mesenchymal stromal cells isolated from Crohn disease patients in a novel Mouse model of Colitis 81
Low-dose methotrexate as treatment of myeloproliferative neoplasms: Proof of principle of clinical activity 80
The “vesicular intelligence” strategy of blood cancers 78
Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge 77
CD 133+ stem cells for the treatment of end stage liver disease. 76
INFLAMMATORY PATHWAYS IN THE BONE MARROW: ROLE OF TIMP-1 IN HEMATOPOIETIC STEM/PROGENITOR CELLS AND LEUKEMIA 76
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 75
CD133+ stem cells for the treatment of end-stage liver disease 69
Process development and validation of expanded regulatory T cells for prospective applications: an example of manufacturing a personalized advanced therapy medicinal product 69
null 68
CD133+ hematopoietic stem cells reinfusion in end-stage liver disease (ESLD): final results of a phase I clinical trial 61
The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis 59
Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60 years. 57
The diagnostic role of next generation sequencing in uncovering isolated splenomegaly: A case report 56
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 52
SPONTANEOUS MOBILIZATIONOF BONE MARROW-DERIVED HEMATOPOIETIC AND ENDOTHELAIL PROGENITOR CELLS AFTER ORTHOTOPIC LIVER TRANSPALNTATION (OLT). 50
Circulating CD4+CD161+CD196+ Th17 cells are not increased in immune thrombocytopenia 50
Circulating extracellular particles from severe COVID-19 patients show altered profiling and innate lymphoid cell-modulating ability 43
Reinfusion of highly purified CD133+ stem cells in patients with end-stage liver disease (ESLD): final results of a phase I clinical trial 40
Telemedicine in patients with haematological diseases during the coronavirus disease 2019 (COVID-19) pandemic: selection criteria and patients’ satisfaction 35
Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years 34
Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients 29
The power of extracellular vesicles in myeloproliferative neoplasms: “Crafting” a microenvironment that matters 29
Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis 25
IDENTIFICATION OF POLYCYTHEMIA VERA-SPECIFIC BIOMARKERS OF OUTCOME BY NOVEL MULTIDIMENSIONAL ANALYSIS APPROACHES 25
Is there a gender effect in polycythemia vera? 17
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 17
A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase 16
Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation 14
null 10
Cancer procoagulant in acute non lymphoid leukemia: Relationship of enzyme detection to disease activity 9
Ascorbic acid for the treatment of chronic refractory idiopathic thrombocytopenic purpura (ITP) 8
Biological characterization of CD34+ cells mobilized into peripheral blood 7
Biological characterization of CD34+ cells mobilized into peripheral blood 7
Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides 7
Characterization of autotransplant-related thrombocytopenia by evaluation of glycocalicin and reticulated platelets 6
Ticlopidine in the treatment of thrombotic thrombocytopenic purpura: Report of two cases 6
Impaired survival of bone marrow GPIIb/IIIa+ megakaryocytic cells as an additional pathogenetic mechanism of HIV-1-related thrombocytopenia 4
Totale 8.750
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.531
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.531
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.733 0 0 12 130 238 210 249 271 279 144 98 102
2020/20211.206 201 67 20 30 46 51 33 62 124 68 48 456
2021/20221.829 118 92 91 194 140 68 48 125 60 203 378 312
2022/20232.094 210 293 120 276 121 175 50 157 367 78 143 104
2023/2024601 48 96 41 75 53 126 27 33 15 41 22 24
2024/2025433 120 265 48 0 0 0 0 0 0 0 0 0
Totale 8.817